Publicaciones en colaboración con investigadores/as de Duke Clinical Research Institute (44)

2023

  1. Anonymous Comparison of Various Angiography-Derived Fractional Flow Reserve Software With Pressure-Derived Physiological Assessment

    JACC: Cardiovascular Interventions, Vol. 16, Núm. 14, pp. 1778-1790

  2. Biolimus-eluting vs. other limus-eluting stents in NSTE-ACS: A pooled analysis of GLASSY and TWILIGHT

    International Journal of Cardiology, Vol. 383, pp. 24-32

  3. Clinically Driven Revascularization in High-Risk Patients Treated With Ticagrelor Monotherapy After PCI: Insights from the Randomized TWILIGHT Trial

    American Journal of Cardiology, Vol. 208, pp. 16-24

  4. External applicability of the Effect of ticagrelor on Health Outcomes in diabEtes Mellitus patients Intervention Study (THEMIS) trial: An analysis of patients with diabetes and coronary artery disease in the REduction of Atherothrombosis for Continued Health (REACH) registry

    International Journal of Cardiology, Vol. 370, pp. 51-57

  5. Survival after Invasive or Conservative Management of Stable Coronary Disease

    Circulation, Vol. 147, Núm. 1, pp. 8-19

2022

  1. A Multicenter, Phase 2, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group, Dose-Finding Trial of the Oral Factor XIa Inhibitor Asundexian to Prevent Adverse Cardiovascular Outcomes After Acute Myocardial Infarction

    Circulation, Vol. 146, Núm. 16, pp. 1196-1206

  2. Bleeding and Ischemic Outcomes With Ticagrelor Monotherapy According to Body Mass Index

    JACC: Cardiovascular Interventions, Vol. 15, Núm. 19, pp. 1948-1960

  3. Safety of the oral factor XIa inhibitor asundexian compared with apixaban in patients with atrial fibrillation (PACIFIC-AF): a multicentre, randomised, double-blind, double-dummy, dose-finding phase 2 study

    The Lancet, Vol. 399, Núm. 10333, pp. 1383-1390

  4. Safety, efficacy, and pharmacokinetics of gremubamab (MEDI3902), an anti-Pseudomonas aeruginosa bispecific human monoclonal antibody, in P. aeruginosa-colonised, mechanically ventilated intensive care unit patients: a randomised controlled trial

    Critical Care, Vol. 26, Núm. 1

  5. Ticagrelor Monotherapy After PCI in High-Risk Patients With Prior MI: A Prespecified TWILIGHT Substudy

    JACC: Cardiovascular Interventions, Vol. 15, Núm. 3, pp. 282-293

  6. Ticagrelor monotherapy after PCI in patients with concomitant diabetes mellitus and chronic kidney disease: TWILIGHT DM-CKD

    European heart journal. Cardiovascular pharmacotherapy, Vol. 8, Núm. 7, pp. 707-716

2021

  1. A prospective multicenter validation study for a novel angiography-derived physiological assessment software: Rationale and design of the radiographic imaging validation and evaluation for Angio-iFR (ReVEAL iFR) study

    American Heart Journal, Vol. 239, pp. 19-26

  2. Cardiovascular Risk and Health Among People With Human Immunodeficiency Virus (HIV) Eligible for Primary Prevention: Insights From the REPRIEVE Trial

    Clinical Infectious Diseases, Vol. 73, Núm. 11, pp. 2009-2022

  3. Impact of Age on the Safety and Efficacy of Ticagrelor Monotherapy in Patients Undergoing PCI

    JACC: Cardiovascular Interventions, Vol. 14, Núm. 13, pp. 1434-1446

  4. Novel Criteria for the Observe-Zone of the ESC 0/1h-hs-cTnT Algorithm

    Circulation, Vol. 144, Núm. 10, pp. 773-787

  5. Reparative cell therapy for the heart: critical internal appraisal of the field in response to recent controversies

    ESC Heart Failure, Vol. 8, Núm. 3, pp. 2306-2309

  6. Ticagrelor monotherapy in patients at high bleeding risk undergoing percutaneous coronary intervention: TWILIGHT-HBR

    European Heart Journal, Vol. 42, Núm. 45, pp. 4624-4634

  7. Ticagrelor monotherapy in patients with chronic kidney disease undergoing percutaneous coronary intervention: TWILIGHT-CKD

    European Heart Journal, Vol. 42, Núm. 45, pp. 4683-4693

2020

  1. Non-hyperaemic coronary pressure measurements to guide coronary interventions

    Nature Reviews Cardiology, Vol. 17, Núm. 10, pp. 629-640

  2. Safety and efficacy of drug eluting stents vs bare metal stents in patients with atrial fibrillation: A systematic review and meta-analysis

    Thrombosis Research, Vol. 195, pp. 128-135